

AGENDA

- 7:00–8:00 AM Registration
- 8:00–8:30 AM Breakfast
- 8:30–8:40 AM Welcome and Introduction
Ira Jacobson, MD

SESSION 1 PBC DISEASE OVERVIEW

Session Chair: Ira Jacobson, MD

- 8:40–9:00 AM Epidemiology and Natural history of PBC
W. Ray Kim, MD
- 9:00–9:20 AM PBC: Updates on pathophysiology, diagnosis, antimitochondrial antibodies (AMA) testing
Joseph Odin, MD
- 9:20–9:40 AM UDCA treatment for PBC: What constitutes a response, and when is it not enough?
Keith Lindor, MD
- 9:40–10:00 AM Evolving data on therapeutic approaches beyond UDCA – FXR and PPAR agonists
Cynthia Levy, MD
- 10:00–10:15 AM Pathology of PBC: Facts and Fibs
Romil Saxena, MD
- 10:15–10:30 AM Panel Discussion and Q&A
- 10:30–11:00 AM **Break**

SESSION 2

INTERACTIVE CASES IN PBC

Session Chair: Keith Lindor, MD

11:00–11:30 AM Case I: Hyperlipidemia and Metabolic bone disease in PBC
Mechanism?
What are we measuring?
What are the risks?
When do we treat?
Cynthia Levy, MD

11:30–12:00 PM Case II: Pruritus and Fatigue in PBC
Pathogenesis and management approaches
Marlyn Mayo, MD

12:00–12:30 PM Case III: Associated autoimmune disease in PBC
Ira Jacobson, MD

12:30–1:15 PM **Lunch**

1:15–1:45 PM Case IV: Overlap syndrome
Diagnostic and management considerations
Joseph Odin, MD, PhD

1:45–2:15 PM Case V: Management issues in PBC patients with advanced
liver disease: Evolution of portal hypertension, screening
for varices and hepatocellular carcinoma
W. Ray Kim, MD

SESSION 3

TABLE BREAKOUTS: CLINICAL CASE DISCUSSIONS

Session Chair: Cynthia Levy, MD

2:15–3:15 PM Diagnostic and therapeutic dilemmas in PBC

3:15–3:45 PM Panel Discussion and Q&A

3:45–4:05 PM **Break**

SESSION 4

SUMMARY SESSION

Session Chair: Ira Jacobson, MD

4:05–4:15 PM Future perspectives on PBC management
Keith Lindor, MD

4:15–4:30 PM Meeting Wrap-up
Ira Jacobson, MD